1%盐酸布替萘芬乳膏治疗浅部真菌病临床观察

目的：评价1％盐酸布替萘芬乳膏治疗浅部真菌病的临床疗效及安全性，并与1％联苯苄唑凝胶进行比较。方法：对83例浅部真菌病患者进行治疗，其中治疗组43例，外用1％盐酸布替萘芬乳膏，每日1次；对照组40例，外用1％联苯苄唑凝胶，每日1次，体股癣疗程2周，手足癣4周。分别于停药及停药2周时观察记录患者的临床表现及治疗效果。结果：1％盐酸布替萘芬乳膏和1％联苯苄唑凝胶临床疗效相似，停药时临床总有效率分别为90．7％和90．0％，真菌总清除率为93．0％和90．0％；停药2周时临床总有效率分别为97．7％和92．5％，真菌总清除率为100．0％和92．5％。不良反应少。结论：1％盐酸布替萘芬乳膏治疗浅部真菌病疗效显著且安全。     

布替萘芬乳膏治疗马拉色菌毛囊炎的疗效观察

为了观察外用盐酸布替萘芬治疗马拉色菌毛囊炎的临床疗效及安全性,我们于2004年9月至2005年6月,用1%盐酸布替萘芬乳膏治疗马拉色菌毛囊炎,并与联苯苄唑乳膏(孚琪乳膏)的疗效进行比较,现将结果报道如下.     

1％布替萘芬霜和复方布替萘芬霜治疗足癣的临床观察

布替萘芬 (ｂｕｔｅｎａｆｉｎｅ)是新一类真菌外用药的代表药物[1] ,我们分别应用 1%布替萘芬霜、加入氯倍他索的复方布替萘芬霜和孚琪 (联苯苄唑 )乳膏治疗足癣 ,现报告如下。1　资料与方法1.1　临床资料　共 15 0例门诊病例 ,均经临床和真菌镜检确诊 ,在 1个月内无内服抗真菌药物及 1周内无外用抗真菌药物 ,分为复方布替萘芬霜治疗组 (Ａ组 )、1%布替萘芬霜治疗组 (Ｂ组 )及联苯苄唑乳膏治疗组(Ｃ组 )。最后完成疗效观察的患者 137例 ,年龄 14～78岁 ,平均 4 3.8± 14.6岁 (见表 1)。1.2　药物　盐酸布替萘芬由我院药剂科合成[2 ] ,按1%…     

美克治疗浅部真菌病有奖征文通知

为了观察外用盐酸布替萘芬治疗马拉色菌毛囊炎的临床疗效及安全性，我们于2004年9月至2005年6月．用1％盐酸布替萘芬乳膏治疗马拉色菌毛囊炎，并与联苯苄唑乳膏（孚琪乳膏）的疗效进行比较，现将结果报道如下。     

1%布替萘芬乳膏治疗体股癣和手足癣疗效观察

目的　探讨 1%布替萘芬乳膏治疗体股癣和手足癣疗效。方法　 82例体股癣和手足癣患者外用布替萘芬乳膏 ,2次 /d ,随访观察症状和体征积分变化情况。结果　布替萘芬乳膏治疗体股癣和手足癣有效率为 93 .9%。结论　布替萘芬乳膏治疗体股癣和手足癣疗效好 ,值得临床选用。     

盐酸布替萘芬软膏治疗浅部真菌病疗效观察

目的探讨盐酸布替萘芬软膏治疗浅部真菌病的临床疗效。方法使用1%盐酸布替萘芬软膏,早、晚各1次薄薄涂于患处,1～4周判断疗效;并以克霉唑软膏作对照。结果盐酸布替萘芬软膏治疗体股癣痊愈率59.01%,有效率和真菌清除率均95.45%;治疗手足癣痊愈率为44.44%,有效率为92.60%,真菌清除率为88.89%;治疗花斑癣痊愈率为56.25%,有效率为93.75%,真菌清除率93.75%。各病种治疗组与对照组治愈率、有效率及真菌清除率分别比较,差异均有统计学意义(P均<0.05)。结论盐酸布替萘芬软膏治疗浅部真菌病安全、有效。     

萘替芬酮康唑乳膏治疗体股癣临床疗效观察

我科于2009年3～9月应用萘替芬酮康唑乳膏治疗体股癣53例,并以联苯苄唑乳膏治疗47例作对照,结果报道如下.     

1%联苯苄唑乳膏治疗手足癣及体股癣的临床研究

目的探讨1%联苯苄唑乳膏治疗手足癣及体股癣的临床疗效和安全性。方法采用多中心、随机、单盲、平行对照法,对照药物为1%硝酸咪康唑乳膏。在停药时和停药1周后记录症状及真菌学检查结果,并评价疗效及不良事件。结果1%联苯苄唑乳膏对手足和体股癣临床疗效、真菌学疗效、不良反应发生率与对照药1%硝酸咪康唑乳膏相似。停药1周后试验组手足癣和体股癣治愈率均高于对照组(P<0.05),但两组的有效率差异均无统计学意义(P=1.000)。结论1%联苯苄唑乳膏治疗手足癣及体股癣安全、有效。     

1%盐酸布替萘芬治疗浅部真菌病临床疗效及安全性观察

选择110例体股癣和手足癣患者外用1%盐酸布替萘芬乳膏,2次/d,随访观察症状和体征积分变化情况。结果:盐酸布替萘芬乳膏治疗体、股癣和手、足癣有效率为97.27%,其疗效好,安全性高,值得临床选用。     

盐酸布替萘芬乳膏联合伊曲康唑治疗念珠菌性龟头炎临床观察

目的观察盐酸布替萘芬乳膏联合伊曲康唑治疗念珠菌性龟头炎的临床疗效。方法将100例患者随机分为两组,各50例。治疗组每天午餐后口服伊曲康唑200mg,同时每日早、晚各1次清洗龟头皮损,拭干后予盐酸布替萘芬乳膏外搽;对照组仅口服伊曲康唑,用法同治疗组。两组疗程均为7天。分别于治疗前及治疗后1个月时进行临床、真菌学疗效观察。结果治疗组有效率94.00%,真菌清除率为98.00%,对照组分别为86.00%和92.00%。两组有效率差异有显著性(P<0.01)。结论盐酸布替萘芬乳膏联合伊曲康唑治疗念珠菌性龟头炎疗效好。     

Off-label use of biologic agents in the treatment of dermatosis, part 2: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab, and cetuximab

In recent years, a series of new drugs have been developed through the application of molecular biology. These drugs act by blocking specific molecules of the immune system and have been developed to act on specific targets that play an important role in the pathophysiology of the diseases in which their therapeutic use has now been approved. Over time, experience has been accumulated in the use of these drugs in the treatment of skin diseases for which they have not been approved but in which the pathophysiology suggests that they could also be effective. The use of these drugs is increasing in difficult-to-treat cases of skin diseases for which the drugs are not approved. The second part of this review of off-label use of biologic agents in dermatology considers the use of etanercept, efalizumab, alefacept, rituximab, basiliximab, omalizumab, and cetuximab.     

Treatment of Paracoccidioidomycosis, Candidiasis, Chromomycosis, Lobomycosis, and Mycetoma with Ketoconazole

ABSTRACT: The authors present the use of ketoconazole in 27 cases of paracoccidioidomycosis, eight of mycetoma, seven of chromomycosis. four of systemic candidiasis and one of lobomycosis. The drug was administered orally in a dosage of 200 to 400 mg per day within a period of up to 90 days. The results of the treatment for paracoccidioidomycosis were of cicatrization of the cutaneous lesions in three to four weeks in 24 patients and in two, from six to seven weeks. Out of 27 patients, 14 presented pulmonary lesions. The evolution within a 90-day period showed radiological cure in one case, improvement in seven, and unaltered picture in five patients. In one there was no further control. In the three out of four cases of candidiasis there was clinical and mycological cure and in one case marked improvement. In seven cases of chromomycosis there was marked improvement in two moderate in four, and slight in one case. There was slight improvement in one case of lobomycosis, and in eight cases of mycetoma moderate improvement in three, slight in three and none in two, but the mycological examinations wore still positive. The drug tolerance was excellent.     

Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up

Vitiligo is an acquired pigmentary disorder of unknown etiology that is clinically characterized by the development of white macules related to the selective loss of melanocytes. The prevalence of the disease is around 1% in the United States and in Europe, but ranges from less than 0.1% to greater than 8% worldwide. A recorded predominance of women may reflect their greater willingness to express concern about cosmetically relevant issues. Half of all patients develop the disease before 20 years of age. Onset at an advanced age occurs but is unusual, and should raise concerns about associated diseases, such as thyroid dysfunction, rheumatoid arthritis, diabetes mellitus, and alopecia areata. Generalized vitiligo is the most common clinical presentation and often involves the face and acral regions. The course of the disease is unpredictable and the response to treatment varies. Depigmentation may be the source of severe psychological distress, diminished quality of life, and increased risk of psychiatric morbidity. Part I of this two-part series describes the clinical presentation, histopathologic findings, and various hypotheses for the pathogenesis of vitiligo based on past and current research.     

Association of auxotypes of Neisseria gonorrhoeae and susceptibility to penicillin G, spectinomycin, tetracycline, cefaclor, cefoxitin, and moxalactam

Isolates of Neisseria gonorrhoeae from 304 patients attending a venereal disease clinic were examined by a plate dilution method for their susceptibility to six antibiotics: penicillin G, spectinomycin, tetracycline, cefaclor, cefoxitin, and moxalactam. The isolates were also characterized by gonococcal auxotyping. The most frequent auxotypes were Nonrequiring, 58%; Pro-, 14%; Pro- Arg (Orn*) Ura-, 14%; Arg- Hyx- Ura-, 6%; and a miscellaneous group consisting of 8% of the isolates. If the entire group of isolates were examined, moxalactam was the most active of the antibiotics; 94% of the isolates were inhibited by less than or equal to 0.25 microgram/ml. The Pro- Arg (Orn*) Ura- isolates were relatively resistant to penicillin G and cefoxitin. The Arg- Hyx- Ura- group of isolates was the most susceptible of the auxotypes to all of the antibiotics except spectinomycin. The uncommon auxotype Arg (Orn*) Ura- has a requirement for arginine that is satisfied by citrulline but not by ornithine. The results of the present study indicate that the nutritional requirements of gonococci may be associated with their response to certain antibiotics.